UCL will be at the forefront of running a new ground-breaking research partnership to develop novel brain tumour treatments in the UK.
The NIHR Brain Tumour Research Consortium is a national partnership of 48 hospitals, universities, cancer centres, charities and patients. Set up with £13.7 million National Institute for Health and Care Research (NIHR) funding, it is a coordinated UK-wide effort to transform outcomes for people living with brain tumours and their families.
The centre will be led by Professor Juanita Lopez at The Royal Marsden NHS Foundation Trust, UCL and Great Ormond Street Hospital's Professor Darren Hargrave (UCL Great Ormond Street Institute of Child Health) and Dr Richard Mair from the Cancer Research UK Cambridge Institute at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust.
Professor Darren Hargrave said: "I would like to thank the NIHR for their funding and support to establish this new national NIHR Brain Tumour Research Consortium, which aims to transform the UK's ability to develop and deliver clinical trials leading to better therapies and improved outcomes for patients and their carers impacted by brain tumours irrespective of age.
"The consortium will bring together the UK's leading clinical researchers and scientists, whilst developing the next generation of researchers in the fight against brain cancer for both children and adults.
"I am honoured to work with Juanita Lopez and Richard Mair in co-leading the consortium. In partnership with colleagues from across the UK, alongside patients and their families and in solidarity with charity and industry partners we aim to rise to the huge challenge to truly make a difference in these devastating diseases."
Professor Lucy Chappell, chief scientific adviser at the Department of Health and Social Care and NIHR chief executive, said: "Brain tumours are one of the most difficult cancers to treat with thousands of people diagnosed each year. This new funding aims to shift the dial in brain tumour research, accelerating the UK towards more life-changing treatments for adults and children with this deadly disease.
"This vital partnership brings together some of the UK's best scientists, health and care professionals, charities and patients to improve lives through cutting-edge research. It demonstrates how NIHR is driving life-changing research for the health of our society, and ensuring more people can be part of research including those from underserved communities."
Minister for Public Health and Prevention, Ashley Dalton, said: "Brain tumours devastate lives, and for too long we haven't had the right tools to tackle them effectively.
"By bringing together our brilliant researchers, NHS teams, charities and patients, we're taking a major step forward in our mission to create an NHS Fit for the Future and ensure fewer lives are lost to the biggest killers. This consortium will help us better understand brain tumours, treat more effectively, and ultimately save lives.
"Everyone deserves the chance to live well for longer, and this research investment is part of our commitment to building a fairer, healthier country."
Shifting the dial in brain tumour research
Brain tumours are among the toughest cancers to treat. This world-leading consortium will help doctors and researchers understand the disease better, test new innovative treatments earlier, and make trials available to more adults and children closer to home.
They will develop and enhance innovative clinical trials focusing on new and emerging treatments through precision medicine (therapies tailored to certain individuals' tumours). In future they hope to expand into new areas such as radiotherapy techniques, and gene and immunotherapies which modify a person's DNA and immune system respectively to tackle cancer. This will create stronger evidence to support future NHS access if treatments prove safe and effective and improve health outcomes.
Aiming to improve survival rates
There are 13,000 new brain, other Central Nervous System (CNS) and intracranial tumour cases in the UK every year making these the eighth most common cancer in the UK, accounting for 3% of all new cancer cases.
The consortium will address five challenges contributing to the current lack of new and effective therapies:
- Large amounts of variation. There are more than 100 brain cancer types and even patients with the same type can be affected differently.
- The limited number of new drugs available for testing.
- Insufficient research facilities, research leaders and research staff.
- Shortcomings in planning and execution of research studies.
- Lack of consistent and dedicated support for brain cancer research.
The partnership has the potential to shift the dial and position the UK as a leading location for brain tumour treatment research. Its activities will include:
- Enrolling patients to a 'real world' study tracking their progress in everyday medical settings, before matching them to new clinical trials based on their cancer subtype.
- Developing pioneering new clinical trials - including platform trials - to test interventions including targeted precision medicines, radiotherapy technologies, immunotherapies, and novel gene therapies.
- Developing new training programmes for those working in brain cancer research to build capacity and increase skills among the next generation of researchers.
- Partnering with patients to ensure the patient's voice is heard in everything we do.
Further NIHR funding into brain tumour treatment trials will be delivered as part of the consortium in early 2026. Research delivered by the consortium will complement research funded and delivered by others, including the Medical Research Council and UK Research and Innovation.
